Article Information
History
- February 17, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Titia Q. Ruijs1,2,
- Catherine M.K.E. de Cuba1,2,
- Jules A.A.C. Heuberger1,
- John Hutchison3,
- Jane Bold3,
- Thomas S. Grønnebæk3,
- Klaus G Jensen3,
- Eva Chin3,
- Jorge A. Quiroz3,
- Thomas K. Petersen3,
- Peter Flagstad3,
- Marieke L. de Kam1,
- Michiel J. van Esdonk1,
- Erica Klaassen1,
- Robert J. Doll1,
- Ingrid W. Koopmans1,2,
- Annika A. de Goede1,
- Thomas H. Pedersen3 and
- Geert Jan Groeneveld1,2,*
- 1Centre for Human Drug Research, 2333 CL, Leiden, The Netherlands
- 2Leiden University Medical Centre, 2333 ZA, Leiden, The Netherlands
- 3NMD Pharma A/S, DK-8200 Aarhus N, Denmark
- ↵*Corresponding author: Professor G.J. Groeneveld, Address: Zernikedreef 8, 2333 CL, Leiden, The Netherlands E-mail: GGroeneveld{at}chdr.nl, Tel: +31 71 52 46 400
Posted February 17, 2024.
SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF A CLC-1 INHIBITOR - A FIRST-IN-CLASS COMPOUND THAT ENHANCES MUSCLE EXCITABILITY: A PHASE I, SINGLE- AND MULTIPLE-ASCENDING DOSE STUDY
